JP2006523682A5 - - Google Patents

Download PDF

Info

Publication number
JP2006523682A5
JP2006523682A5 JP2006507478A JP2006507478A JP2006523682A5 JP 2006523682 A5 JP2006523682 A5 JP 2006523682A5 JP 2006507478 A JP2006507478 A JP 2006507478A JP 2006507478 A JP2006507478 A JP 2006507478A JP 2006523682 A5 JP2006523682 A5 JP 2006523682A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
agonist
polypeptide
subject
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006507478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006523682A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/008833 external-priority patent/WO2004084835A2/en
Publication of JP2006523682A publication Critical patent/JP2006523682A/ja
Publication of JP2006523682A5 publication Critical patent/JP2006523682A5/ja
Pending legal-status Critical Current

Links

JP2006507478A 2003-03-21 2004-03-22 インターロイキン−２１／インターロイキン−２１受容体のアゴニストを用いた免疫学的障害の治療 Pending JP2006523682A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45692003P 2003-03-21 2003-03-21
PCT/US2004/008833 WO2004084835A2 (en) 2003-03-21 2004-03-22 Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor

Publications (2)

Publication Number Publication Date
JP2006523682A JP2006523682A (ja) 2006-10-19
JP2006523682A5 true JP2006523682A5 (enExample) 2007-06-07

Family

ID=33098171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006507478A Pending JP2006523682A (ja) 2003-03-21 2004-03-22 インターロイキン−２１／インターロイキン−２１受容体のアゴニストを用いた免疫学的障害の治療

Country Status (17)

Country Link
US (1) US20060159655A1 (enExample)
EP (1) EP1608315A4 (enExample)
JP (1) JP2006523682A (enExample)
KR (1) KR20060015482A (enExample)
CN (1) CN1849131A (enExample)
AU (1) AU2004224277A1 (enExample)
BR (1) BRPI0408523A (enExample)
CA (1) CA2518854A1 (enExample)
CO (1) CO5611161A2 (enExample)
CR (1) CR7994A (enExample)
EC (1) ECSP056027A (enExample)
IL (1) IL198102A0 (enExample)
MX (1) MXPA05010035A (enExample)
NO (1) NO20054343L (enExample)
RU (1) RU2005132458A (enExample)
WO (1) WO2004084835A2 (enExample)
ZA (1) ZA200507235B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
MXPA05000655A (es) 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
MXPA05009556A (es) * 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP1753458A4 (en) * 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
MX2007001509A (es) * 2004-08-05 2007-03-27 Wyeth Corp Antagonismo de la actividad del receptor de interleuquina 21.
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
AU2006237329B2 (en) 2005-04-18 2012-04-12 Novo Nordisk A/S IL-21 variants
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
EP1960433A2 (en) * 2005-11-28 2008-08-27 Zymogenetics, Inc. Il-21 receptor antagonists
EP2217268B1 (en) * 2007-12-07 2016-05-04 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
WO2009100035A2 (en) * 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
CN102149403A (zh) * 2008-05-23 2011-08-10 惠氏有限责任公司 利用白介素-21受体结合蛋白的治疗方法
AR071885A1 (es) 2008-05-23 2010-07-21 Wyeth Corp Proteinas de union al receptor de interleuquina 21
WO2010039533A2 (en) 2008-09-23 2010-04-08 Wyeth Methods for predicting production of activating signals by cross-linked binding proteins
ES2632213T3 (es) 2008-10-08 2017-09-11 Cambridge Enterprise Limited Métodos y composiciones para diagnosticar y tratar una enfermedad autoinmunitaria que es secundaria con respecto a la esclerosis múltiple
CN107029223A (zh) * 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
ES2716865T3 (es) * 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
EP3978512A1 (en) 2015-10-09 2022-04-06 Bioniz, LLC Modulating gamma-c-cytokine activity
KR102908806B1 (ko) 2015-10-22 2026-01-07 주노 테라퓨틱스 게엠베하 세포의 배양 방법 및 이를 위한 키트와 장치
KR102707650B1 (ko) 2017-04-07 2024-09-19 바이오니즈 테라퓨틱스, 아이엔씨. 감마-c-사이토카인 활성의 안정한 조절자
WO2020009437A1 (ko) * 2018-07-04 2020-01-09 서울대학교산학협력단 신경손상의 면역세포치료
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
WO2020047333A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CA3109139A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Methods of treating aging-related disorders
BR112021021878A2 (pt) 2019-05-03 2022-01-18 Bioniz Llc Modulação dos efeitos de sinalização da gama-c-citocina para tratamento da alopecia e distúrbios associados
AU2020294797B2 (en) 2019-06-21 2025-12-18 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
CN116670163A (zh) 2020-02-11 2023-08-29 Hcw生物科技公司 治疗年龄相关疾病和炎性疾病的方法
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
AU2021262794B2 (en) 2020-04-29 2026-06-18 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
BR112022022652A2 (pt) * 2020-05-08 2023-01-17 Alastin Skincare Inc Composições e métodos para modular inflamação e cicatrização de ferida
IL298608A (en) 2020-06-01 2023-01-01 Hcw Biologics Inc Methods for treating disorders related to aging
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
US12594323B2 (en) 2022-04-13 2026-04-07 Immunitybio, Inc. Methods of reducing neuroinflammation
CN120858116A (zh) * 2023-01-06 2025-10-28 泰温治疗私人有限公司 抗原结合分子

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010025022A1 (en) * 1997-11-26 2001-09-27 Kikly Kristine Kay Hnovilr
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
JP2002516103A (ja) * 1998-05-29 2002-06-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド インターロイキン２１およびインターロイキン２２
AU5104799A (en) * 1998-08-04 2000-02-28 Regeneron Pharmaceuticals, Inc. Novel orphan cytokine receptors
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US20020090680A1 (en) * 1999-05-18 2002-07-11 Millennium Pharmaceuticals, Inc. Novel IL-9/IL-2 receptor-like molecules and uses thereof
ES2279809T3 (es) * 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
EP3254687A1 (en) * 2001-10-04 2017-12-13 Genetics Institute LLC Methods and compositions for modulating interleukin-21 receptor activity
EP2130919A1 (en) * 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21 antagonists
CA2481304A1 (en) * 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
MXPA04012116A (es) * 2002-06-07 2005-04-19 Zymogenetics Inc Uso del il-21 en cancer y otras aplicaciones terapeuticas.
MXPA05000655A (es) * 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
MXPA05009556A (es) * 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
EP1753458A4 (en) * 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
MX2007001509A (es) * 2004-08-05 2007-03-27 Wyeth Corp Antagonismo de la actividad del receptor de interleuquina 21.
US7533965B2 (en) * 2005-03-07 2009-05-19 Eastman Kodak Company Apparatus and method for electrostatically charging fluid drops
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis

Similar Documents

Publication Publication Date Title
RU2005132458A (ru) Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21
Okiyama et al. Therapeutic effects of interleukin‐6 blockade in a murine model of polymyositis that does not require interleukin‐17A
Soriano et al. IL-1β biological treatment of familial Mediterranean fever
CN105392497B (zh) 以il-4r抑制剂治疗嗜酸性食管炎的方法
US20090092604A1 (en) Method for the Treatment of Multiple Sclerosis by Inhibiting IL-17 Activity
RU2411042C2 (ru) Композиции и способы для лечения острого респираторного синдрома (sars)
US20060024268A1 (en) Modulation of immunoglobulin production and atopic disorders
JP2013227340A (ja) 可溶性リンホトキシンβレセプターによる脱髄障害の処置
DE112012000404T5 (de) Modulatoren von IL-12 und/oder IL-23 zur Prävention oder Behandlung des Morbus Alzheimer
Campbell et al. Immunomodulatory effects of etanercept in a model of brain injury act through attenuation of the acute‐phase response
TWI363091B (en) Uses of mammalian cytokine; related reagents
Hess et al. High doses of interleukin‐12 inhibit the development of joint disease in DBA/1 mice immunized with type II collagen in complete Freund's adjuvant
KR20230086674A (ko) 파킨슨 질환의 치료
CN121177504A (zh) 靶向刺激免疫分子在制备预防和治疗自然衰老药物、保健品和化妆品中的用途
JP2016527326A (ja) ベンラリツマブによる喘息症状の改善方法
Lauenstein et al. Pituitary adenylate cyclase‐activating peptide receptor 1 mediates anti‐inflammatory effects in allergic airway inflammation in mice
JP2019501925A (ja) Ｇｄｆ１１での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する
US20230364192A1 (en) Modulation of beta cell regeneration through gpr75 signaling
KR20210042138A (ko) 건선 치료 방법
KR20040030948A (ko) 과민성 질환에 효과적인 ｉｌ-18 저해물질
TW202532439A (zh) 治療氣喘之方法
Mehlis et al. Tumor necrosis factor (TNF)
Swendrowski Ustekinumab: a review of the effectiveness of targeting interleukin-12/23P40 in psoriasis and other immune-mediated diseases
Cingoz et al. Ustekinumab (Stelara® 1) 2
Hammer Modulation of the OGF-OGFr axis alters the disease course of relapse remitting experimental autoimmune encephalomyelitis